Join us for a fascinating conversation with Greg Ramey, Managing Director of BermudAir Holidays, and Jessica Steinberg, Travel Packaging Marketing Manager at Switchfly, as we explore the evolution of Bermuda’s flagship airline. Discover how BermudAir is enhancing the travel experience by combining local expertise with innovative packaging solutions and a commitment to exceptional service. From debunking Bermuda Triangle myths to celebrating community milestones and uncovering the island’s unique business landscape, this episode offers rich insights and memorable stories for anyone curious about travel and transformation in the airline industry. Don’t miss this behind-the-scenes look at how Swithfly technology and effective teamwork with BermudAir are shaping Bermuda’s hospitality and future destinations.Check out BermudAir todayWebsite: https://www.flybermudair.com/en/Connect with SwitchflyWebsite: https://www.switchfly.com/LinkedIn: https://www.linkedin.com/company/switchfly/X: https://twitter.com/switchflyYouTube: https://www.youtube.com/@SwitchflyOfficialChapters(00:01) Introductions and Setting the Stage(01:17) Bermuda Triangle Myth and Island Overview(02:18) Evolution of Bermudaire’s Packaging Services(05:20) Company Profile and Unique Bermuda Aspects(09:25) Local Pride and Unexpected Stories(10:54) Impact of Switchfly Technology and Collaboration(16:21) Future Plans and Anguilla Expansion(19:06) Highlighting Bermuda’s Culture and Final Thoughts(19:57) Personal Travel Favorites and MilestonesKeywords: Bermuda travel, Bermudair, Switchfly, island airline, travel loyalty, travel packaging, hospitality, Bermuda Triangle, Anguilla flights, travel innovation, airline technology

In this episode of "In the Interim…", Dr. Scott Berry chats with Frank Harrell, a professor of Biostatistics at Vanderbilt University and W.J. Dixon Award winner. Harrell describes his transition from frequentist to Bayesian clinical trial design, prompted by a decisive meeting with Dr. Don Berry, informed by David Spiegelhalter’s published work. The dialogue addresses persistent academic opposition to Bayesian methods, operational constraints in trial implementation, regulatory work at FDA, and technical Bayesian modeling details.Key HighlightsHarrell credits Don Berry’s direct influence for converting him to Bayesian methods during his early career at Duke, despite entrenched academic resistance.Discusses early cardiovascular research at Duke, experiences with large multicenter trials, and later founding Vanderbilt’s Biostatistics department.Details the compromise of using Bayesian interim monitoring and frequentist primary analyses under NIH and regulatory mandates.Outlines design and publication of the ORBITA cardiovascular trial (Imperial College London), using all-Bayesian longitudinal ordinal methodology—Lancet reviewers required all analyses remain Bayesian, rejecting inclusion of a mixing frequentist and Bayesian analyses.Critiques simulation of Type 1 error within Bayesian trial designs.Addresses deficiencies in eliciting utilities for clinical endpoints, underscoring operational challenges in longitudinal ordinal modeling and ethical imperatives for efficient early stopping.

On this episode of the AWM NFL Players' Podcast, host Riccardo Stewart is joined by Jeff Locke, Sam Acho, and Zach Miller to break down a topic every pro needs to understand: target date funds. The team shares firsthand stories, demystifies how target date funds work, and examines why these investments may not be the right play for high-net-worth NFL athletes. With real numbers, honest, hard-earned perspectives, and actionable advice, this episode offers the insider knowledge you need to make smarter decisions for your financial future. If you want to know what works—and what could be costing you millions—this conversation is a must-listen.Connect with usCall or text: 602-989-5022Website: https://www.athletefamilyoffice.com/LinkedIn: https://www.linkedin.com/company/awmcapital/Instagram: https://www.instagram.com/awmcapital/Facebook: https://www.facebook.com/awmcapital/X: https://twitter.com/awmcapitalChapters(00:01) Family stories and investment analogies(02:01) First encounters with target date funds(03:03) What is a target date fund(04:15) Advantages and origins of target date funds(05:45) Disadvantages for NFL athletes(07:29) Why customization matters for high-net-worth athletes(09:57) Next steps if you have a target date fund